Form 4 Filing for Wiley Matthew T. at Definium Therapeutics, Inc.

This filing details a transaction by Wiley Matthew T., Chief Commercial Officer at Definium Therapeutics, Inc. (DFTX). On June 25, 2026, Mr. Wiley sold 2,867 shares of Common Stock at a price of $45.03 per share. This sale was to cover tax withholding obligations upon the settlement of vested restricted stock units. The transaction was executed under a Rule 10b5-1 plan adopted on May 29, 2025. Following this transaction, Mr. Wiley holds 174,633 shares of Common Stock. The filing is a Form 4, indicating a change in beneficial ownership.